DK1044005T3 - 1,2,4-Benzotriazinoxidformuleringer - Google Patents

1,2,4-Benzotriazinoxidformuleringer

Info

Publication number
DK1044005T3
DK1044005T3 DK98915529T DK98915529T DK1044005T3 DK 1044005 T3 DK1044005 T3 DK 1044005T3 DK 98915529 T DK98915529 T DK 98915529T DK 98915529 T DK98915529 T DK 98915529T DK 1044005 T3 DK1044005 T3 DK 1044005T3
Authority
DK
Denmark
Prior art keywords
oxide formulations
benzotriazine oxide
benzotriazine
formulations
treatment
Prior art date
Application number
DK98915529T
Other languages
Danish (da)
English (en)
Inventor
Stephen Brown
Edward Baker
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Application granted granted Critical
Publication of DK1044005T3 publication Critical patent/DK1044005T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
DK98915529T 1997-04-21 1998-04-14 1,2,4-Benzotriazinoxidformuleringer DK1044005T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/837,637 US5827850A (en) 1995-09-25 1997-04-21 1,2,4-benzotriazine oxides formulations

Publications (1)

Publication Number Publication Date
DK1044005T3 true DK1044005T3 (da) 2006-09-25

Family

ID=25275027

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98915529T DK1044005T3 (da) 1997-04-21 1998-04-14 1,2,4-Benzotriazinoxidformuleringer

Country Status (13)

Country Link
US (2) US5827850A (fr)
EP (1) EP1044005B1 (fr)
JP (1) JP2001523248A (fr)
AT (1) ATE332139T1 (fr)
AU (1) AU6969098A (fr)
BR (1) BR9808958A (fr)
CA (1) CA2287257C (fr)
DE (1) DE69835167T8 (fr)
DK (1) DK1044005T3 (fr)
ES (1) ES2267183T3 (fr)
NO (1) NO325275B1 (fr)
PT (1) PT1044005E (fr)
WO (1) WO1998047512A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616584A (en) * 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
CA2456569A1 (fr) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Mono-n-oxides de benzoazine et 1,4-dioxides de benzoazine et compositions a base de ceux-ci pour usage therapeutique dans les traitements de cancers
EP2543376A1 (fr) 2004-04-08 2013-01-09 Targegen, Inc. Inhibiteurs de benzotriazine de kinases
MX2007002208A (es) 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
CN101683319B (zh) * 2008-09-24 2012-09-05 杭州民生药业有限公司 一种替拉扎明非肠道给药含水制剂及其制备方法
CN101683346B (zh) * 2008-09-24 2015-04-01 杭州民生药业有限公司 一种替拉扎明非肠道含水制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) * 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
CZ292102B6 (cs) * 1995-09-25 2003-07-16 Sanofi-Synthelabo Inc. Vodný parenterální prostředek pro léčbu rakovinových nádorů

Also Published As

Publication number Publication date
US6153610A (en) 2000-11-28
DE69835167T2 (de) 2007-06-06
BR9808958A (pt) 2000-08-01
DE69835167D1 (de) 2006-08-17
NO325275B1 (no) 2008-03-17
EP1044005B1 (fr) 2006-07-05
PT1044005E (pt) 2006-10-31
EP1044005A1 (fr) 2000-10-18
JP2001523248A (ja) 2001-11-20
CA2287257A1 (fr) 1998-10-29
ATE332139T1 (de) 2006-07-15
EP1044005A4 (fr) 2001-08-08
CA2287257C (fr) 2007-06-12
US5827850A (en) 1998-10-27
AU6969098A (en) 1998-11-13
ES2267183T3 (es) 2007-03-01
NO995109D0 (no) 1999-10-20
WO1998047512A1 (fr) 1998-10-29
NO995109L (no) 1999-12-21
DE69835167T8 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
ZA921911B (en) 2,4-diaminoquinazoline derivatives for enhancing anti-tumor activity.
NO20026245D0 (no) Forbedring av antistoff-cytokin-fusjonsprotein-formidlede immunresponser ved kombinert behandling med immunocytokin-opptaksökende midler
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
ITMI990375A1 (it) Trattamento del cancro co epotiloni
NO993654L (no) Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker
IL134445A0 (en) A method of preventing or treating estrogen-dependent diseases and disorders
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
DK1044005T3 (da) 1,2,4-Benzotriazinoxidformuleringer
MXPA03011306A (es) Metodos para la preparacion y uso de 1a,24 (s) - hidroxivitamina d2.
MY137303A (en) Methods for treating proliferative diseases
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
EP1364657A4 (fr) Remedes contre les tumeurs affectant les organes hematopoietiques
CY1106525T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ hCG ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ
CA2232989A1 (fr) Formulations d'oxydes de 1,2,4-benzothriazine
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
SE0100684D0 (sv) New subject-matter
ZA200203166B (en) Treatment of cancer.
AU1128801A (en) Agents for treating human diseases, especially for treating tumors such as colonic cancers and melanomas or for regenerating tissue and promoting hair growth
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
AU2001291256A1 (en) Methods and compositions for the identification, assessment and therapy of human cancers